KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

Hubert H Fernandez, Stuart H Isaacson, Robert A Hauser, Pinky Agarwal, William Ondo, Ariane Park, Daniel Kremens, Matthew Leoni, Sridhar Duvvuri, Cari Combs, Erica Koenig, Ih Chang, Gina Pastino, Stacey Tringali, Nicole Golonski, Raymond Sanchez, Linda Harmer, Joey Boiser, Cindy Zadikoff, Zoltan Mari

JAMA Neurol 83(5) 442-451

PMID41860544
PMCIDPMC13005180
DOI10.1001/jamaneurol.2026.0577
发表日期2026-03-20
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线。
摘要

摘要

IMPORTANCE: Development of motor fluctuations is common in people with Parkinson disease (PD) treated with oral levodopa, and currently available dopamine (D) agonists adjunctive to levodopa offer additional motor control but may increase risk of adverse events (AEs) via preferential activation of D2/D3 receptors. Tavapadon is a novel, investigational, oral, once-daily, selective D1/D5 agonist that may improve motor control while minimizing AEs commonly associated with D2/D3 receptor activation. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of tavapadon as adjunctive therapy to oral levodopa in adults with PD experiencing motor fluctuations. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 3, double-blind, placebo-controlled randomized clinical trial conducted between September 2020 and February 2024 with a 4-week safety follow-up. Participants were recruited from 148 sites across 14 countries. Participants were enrolled after screening adults with PD who were experiencing fluctuations while receiving stable oral levodopa (≥400 mg daily). INTERVENTIONS: Participants were randomized 1:1 to flexible-dose tavapadon (5-15 mg once daily) or placebo adjunctive to oral levodopa for 27 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was change from baseline to week 26 in total daily on-time (ie, good mobility, smoother movement, fewer motor/nonmotor symptoms) without troublesome dyskinesia (referred to as good-on-time). The key secondary end point was change from baseline in total daily off-time (ie, return/worsening of motor/nonmotor symptoms often experienced between medication doses). RESULTS: After screening 824 adults with PD, 507 participants (mean [SD] age, 64.9 [8.5] years; 321 male [63%]; mean [SD] disease duration, 6.7 [4.5] years; mean [SD] baseline daily off-time, 5.5 [2.4] hours) were enrolled and received tavapadon (n = 252) or placebo (n = 255). Tavapadon significantly increased daily good-on-time by 1.10 hours compared with placebo (1.70 vs 0.60 hours; 95% CI, 0.60-1.70; P <.001). Daily off-time was significantly reduced from baseline with tavapadon vs placebo (-1.88 vs -0.93 hours; difference, -0.94 hours; 95% CI, -1.48 to -0.41]; P < .001). Tavapadon had a favorable safety profile; although more AEs occurred with tavapadon vs placebo (180 participants [71.7%] vs 140 participants [55.1%]), most were nonserious (93.2%) and mild to moderate in severity. Common AEs with tavapadon (≥5% of participants) were nausea (14.3%), dyskinesia (10.0%), and dizziness (7.6%). CONCLUSIONS AND RELEVANCE: Findings of this randomized clinical trial demonstrate the efficacy, tolerability, and safety profile of tavapadon adjunctive to levodopa for off fluctuations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04542499.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Flowchart Depicting the TEMPO-3 Study Design and Participant Disposition mITT indicates modified intention to treat; TEMPO-3, Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson Disease With Motor Fluctuations. a Diagnosis of Parkinson disease (PD) consistent with UK Parkinson Disease Brain Bank diagnostic criteria. b Good response to levodopa and receiving a minimum stable dose of ≥400 mg per day (minimum 3-4 daily doses [≥3 doses of extended release levodopa/carbidopa or ≥4 doses of standard levodopa/carbidopa]). c Tavapadon was titrated over 6 weeks to a 5-mg once-daily dose and blinded dose adjustment up to 15 mg once daily (maximum-tolerated dose) by week 14. d Placebo treatment was on a background of levodopa. e Primary end point was the change from baseline to end point in the total on time without troublesome dyskinesia (good-on-time) based on the 2-day average of the Hauser diary. f Adverse events (AEs) and concomitant medications were recorded; nonserious AEs were followed up through week 31 and serious AEs were followed up to resolution. g Safety analysis set. h Efficacy analysis included the mITT population: all randomized participants who received at least 1 dose of study drug and had valid baseline and postbaseline Hauser diary assessments.
非 KM Figure
Figure 2.Line Graphs Showing the Least-Squares Mean Change From Baseline in Daily On-Time (Hours) Without Troublesome Dyskinesia (Good-on-Time) and Off-Time in the mITT Population Data based on the 2-day average of Hauser diary entries recorded at 30-minute intervals for 24 hours on 2 consecutive days. Good-on-time is defined as the sum of on time without dyskinesia and on-time with nontroublesome dyskinesia. Error bars are the SE. Nominal significance level of comparison with placebo without multiplicity adjustment except for primary time point. LSM indicates least-squares mean; mITT, modified intention to treat. a P < .05. b P < .01. c P < .001. d No deviations in the titration schedule up through 5 mg (week 8) were allowed. e Dose adjustments were based on individual participant tolerability. f Participants received the highest tolerated dose level that was achieved during the dose adjustment phase (5 mg, 22 participants [8.8%]; 10 mg, 32 participants [12.7%]; 15 mg, 169 participants [67.3%]). No adjustment in the tavapadon dose was allowed during the maintenance phase. Analysis was based on mixed models for repeated measures, with fixed effects for treatment group, visits, and treatment by visit interaction, and participant as a random effect.
非 KM Figure
Figure 3.Bar Graphs Depicting Hauser Diary Motor States Across the Normal Waking Day at Baseline and Week 26 Analysis of normal waking day was based on normalized waking hours of 16 hours per day for each individual patient. Good-on-time is defined as the sum of on time without dyskinesia and on-time with nontroublesome dyskinesia. P values indicate significant treatment difference in least-squares mean change from baseline to week 26. a P < .05. b P < .01.
非 KM Figure